Har ikke lest intervjuet før så måtte google etter du postet 
" Targovax’s chief medical officer, Magnus Jaderberg, told pharmaphorum in an interview that the Viralytics deal came as no surprise following strong phase 2 results from its Cavatak in 2017, based on the Coxsackievirus.
Magnus Jaderberg
Jaderberg said: “As soon as they released the data, we felt that somebody would go after them and we were right. We were not surprised about the deal and we think it is very positive for us.”
He expects more interest in oncolytic viruses from Roche and Genentech, which so far have not done a deal in the technology.
Already partnered with AstraZeneca’s MedImmune on one deal, Targovax is planning a phase 2 trial of its RAS neoantigen vaccine TG01, targeting resected pancreatic cancer in combination with a checkpoint inhibitor.
This could be extended to a phase 3 trial leading to registration in this disease, where there has been no significant progress for the best part of two decades CHECK.
Targeting RAS mutations, the drug could be used in 30% of all cancers that express this biomarker, suggesting a sales potential well in excess of the $400 million a year the company forecasts if approved in early pancreatic cancer.
Also in the Targovax pipeline is ONCOS-102. This works on the distinct adenovirus platfom, and is in phase 1b/2 trials for mesothelioma, in which it is expected to produce an early readout in the first half of 2018.
ONCOS-102 is also being developed in partnership with MedImmune and the Cancer Research Institute for ovarian and colorectal cancer.
Jaderberg has been busy tapping up his contacts in big pharma having previously worked as chief medical officer for Bristol Myers Squibb in Europe.
He has already been in talks with manufacturers of checkpoint inhibitors to enable access for further development.
Wiklund said: “It is tough as a small biotech to lift a phase 3 programme – it is obvious we are interested in licensing out one or both of our programmes.”
But Targovax’s CFO Erik Digman Wiklund was cagey about the prospects of a big buyout as seen in the case of Viralytics. “It is incredibly unpredictable, it is difficult to make any comment,” he said."
Mye mulig du er inne på noe der ja. Trodde det var fond som de forvaltet for kunder. Men du har kanske rett i at det ikke er det.